HLAG Antikörper (C-Term) (FITC)

Produktnummer ABIN302011

Dieses Maus Monoklonal-Antikörper erkennt spezifisch HLAG in ICFC. Er zeigt eine Reaktivität gegenüber Human und wurde in 4+ Publikationen erwähnt.

Kurzübersicht für HLAG Antikörper (C-Term) (FITC) (ABIN302011)

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser HLAG Antikörper ist konjugiert mit FITC

Applikation: Intracellular Flow Cytometry (ICFC)

Klon: 2A12

Produktdetails anti-HLAG Antikörper (FITC)

Bindungsspezifität: C-Term

Verwendungszweck: Anti-HLA-G FITC

Spezifität: The antibody 2A12 was generated to a peptide corresponding to C-intron 4-encoded sequence. This antibody does not crossreact with the full-length HLA-G1 isoform and thus allows to distinguish between secreted HLA-G5 and HLA-G6 isoforms from shedded HLA-G1.

Kreuzreaktivität (Details): Human

Aufreinigung: Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: C-terminal amino acid sequence (22-mer) of soluble HLA-G5 and HLA-G6 proteins coupled to ovalbumin.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow cytometry: Excellent for intracellular staining, recommended dilution: 1-5 μg/mL.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze.
Avoid prolonged exposure to light.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

Referenzen für anti-HLAG Antikörper (FITC) (ABIN302011)

Poláková, Železníková, Russ: "HLA-G5 in the blood of leukemia patients and healthy individuals." in: Leukemia research, Vol. 37, Issue 2, pp. 139-45, (2013) (PubMed).

Larsen, Bzorek, Pass, Larsen, Nielsen, Svendsen, Lindhard, Hviid: "Human leukocyte antigen-G in the male reproductive system and in seminal plasma." in: Molecular human reproduction, Vol. 17, Issue 12, pp. 727-38, (2011) (PubMed).

White, Loisel, McConville, Stern, Tu, Marroquin, Noth, Ober: "Levels of soluble human leukocyte antigen-G are increased in asthmatic airways." in: The European respiratory journal, Vol. 35, Issue 4, pp. 925-7, (2010) (PubMed).

LeMaoult, Le Discorde, Rouas-Freiss, Moreau, Menier, McCluskey, Carosella: "Biology and functions of human leukocyte antigen-G in health and sickness." in: Tissue antigens, Vol. 62, Issue 4, pp. 273-84, (2003) (PubMed).

Details zu HLAG

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Andere Bezeichnung: HLA-G

Hintergrund: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

Gen-ID: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response